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Abstract 
Objective: Herpes simplex virus-2 (HSV-2) infections are almost exclusively sexually transmitted. The presence of 
vaginal gels during sexual activity may have a significant positive or negative impact on viral transmission. Therefore 
we investigated three off-the-shelf vaginal lubricants and one pH restoring gel to evaluate their impact on HSV-2 
replication.
Results: HeLa cells were infected with untreated virions and virions incubated with the particular gels. The accumu-
lation of viral genomes was monitored by quantitative PCR (qPCR) method at 24 h post infection. Two of the tested 
gels had no significant effect on HSV-2 replication at the maximum applied concentration, while two had a strong 
inhibitory effect (~ 98% reduction of replication). The replication inhibitory effect was observed at various multiplicity 
of infection (MOI 0.4–6.4) and the two inhibitory gels were also capable of inhibiting the HSV-2 induced cytopathic 
effect on HeLa cells. The surface tension decreasing activity—an indication of detergent activity—was strongly 
correlated with the anti-HSV-2 activity of the gels  (R2: 0.88). Our results indicate that off-the-shelf vaginal gels have a 
markedly different anti-HSV-2 activity that may influence HSV-2 transmission.
Keywords: Herpes, Simplex, HSV, Replication, Transmission, Gel, qPCR, Vaginal, STD
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds 
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://crea-
tivecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdo-
main/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
HSV-2, a member of the family Herpesviridae, is an 
enveloped DNA virus. Herpes simplex virus infections 
spread through direct contact with body fluids, and in the 
case of HSV-2 the transmission is principally sexual. The 
seroprevalence of HSV-2 indicates that a significant part 
of the population harbors the virus [1]. Herpes genitalis, 
the primary clinical manifestation of HSV-2 infection 
is local and mainly includes vesicles and ulcers. Genital 
herpes can lead to significant clinical complications such 
as neonatal herpesvirus encephalitis [2] and an increase 
in risk of HIV transmission [3]. Similarly to other herpes-
viruses, HSV-2 persistence is common and periodic reac-
tivation with and without clinical symptoms is frequent 
[4]. During reactivation, HSV-2 can be found in vaginal 
lesions and secretions and can be transmitted. The cer-
vicovaginal microenvironment can profoundly influence 
HSV-2 transmission. Previous in vitro and epidemiology 
studies showed that the presence of various Lactobacillus 
species could inhibit HSV-2 development and reduce the 
prevalence of HSV-2 [5–8]. Chemical compounds such as 
vaginal gels applied during or before sexual intercourse 
could also influence the effectivity of HSV-2 transmis-
sion. Incorporating microbicides into vaginal gels is a 
well-accepted strategy for inhibiting sexually transmit-
ted disease transmission including HSV-2 transmission 
[9–11]. We also showed that even basic components of 
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the vaginal gels, such as the gelling agent hydroxyethyl 
cellulose can also significantly influence the replication of 
sexually transmitted pathogens such as Chlamydia tra-
chomatis [12].
We recently developed a direct qPCR method with 
which we can accurately measure herpesvirus genome 
accumulation in the infected cells in  vitro and the rep-
lication inhibitory effects of antiviral drugs and neu-
tralizing antibodies [13]. We applied this technology to 
investigate the effect of off-the-shelf vaginal lubricants 
and a pH restoring gel on the effectivity of HSV-2 infec-
tion of HeLa cervical epithelial cells.
Main text
Materials and methods
Characterization of the maximum non‑toxic concentrations 
of the applied vaginal gels
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was performed to calculate the 
maximum non-toxic concentration of the tested four 
vaginal gels (lubricants: Gel-1, Gel-2, Gel-4; pH restor-
ing gel: Gel-3). The minimum essential medium (MEM) 
with Earle’s salts completed with 10% fetal bovine serum 
(FBS), 2  mmol/L l-glutamine, 1 × nonessential amino 
acids, 25  μg/mL gentamicin and 0.5  μg/mL fungi-
zone on HeLa cells was complemented with serial two-
fold dilutions of the vaginal gels for each concentration 
(n = 3). The initial concentrations of the vaginal gels were 
20 w/v% and further dilutions were performed in MEM. 
After a 24-h incubation, an MTT assay was performed as 
described earlier [14]. All reagents were purchased from 
SIGMA (St. Louis, MO, USA), if otherwise not indicated.
Assessment of the impact of vaginal gels on HSV‑2 replication 
by direct qPCR
A clinical HSV-2 strain isolated in the Department of 
Medical Microbiology (University of Szeged, Szeged, 
Hungary) was used [13, 15]. HeLa cells (6 × 104 cells/
well) were seeded into 96-well plates in 100  µL MEM. 
Next day the HeLa cells were infected with HSV-2 (MOI 
0.1) preincubated with a vaginal gel for 1 h, at 37 °C. After 
the infection (1  h, 37  °C, 5%  CO2), the inoculum was 
removed and MEM, 10% FBS medium was added. Each 
gel concentration was tested in three parallel wells. 24-h 
post infection, the cells were washed twice with phos-
phate buffered saline (PBS) and were subjected to two 
freeze–thaw cycles in 100 μL Milli-Q water to extract the 
viral DNA. 1 μL of the cell lysates were used as templates 
in a direct qPCR as described previously [13]. Statistical 
comparisons of treated samples vs untreated controls 
(cycle threshold (Ct) values) were performed by Student’s 
t-test as described previously [16].
Measurement of the impact of vaginal gels on the surface 
tension
The surface tension measurements of diluted gel solu-
tions were performed on a K100 MK2 Tensiometer 
(Krüss Co., Hamburg, Germany) using the Wilhelmy 
plate method. The initial concentration of the gel aque-
ous dilutions was 1.5  g/L for each samples. The surface 
tension was measured at different concentrations by plac-
ing a 40 mL volume of sample solution in sample recepta-
cle and diluting it with deionized water from a connected 
Dosimat 765 (Metrohm, Herisau, Switzerland) titration 
stand. The solutions were immersed in a constant tem-
perature bath at the desired temperature (25 ± 0.02  °C). 
During the automatized surface tension measurements 
the tensiometer and the dosing unit was controlled using 
the modularly constructed LabDesk™ software.
Results
Impact of vaginal gels on the viability of HeLa cells
In order to exclude the potential HSV-2 replication 
inhibitory effects of the vaginal gels due to the inhibi-
tion of the host cell metabolism, we measured HeLa cell 
viability after 24 h of incubation (Additional file 1: Figure 
S1). Except for Gel-3, cytotoxicity was not observed even 
at the maximal applied concentration of 20 w/v%. Inter-
estingly, for Gel-1 we were even able to detect a moderate 
increase of cell viability at the highest concentration. We 
treated the 20  w/v% (Gel-1, Gel-2, Gel-4) and 10  w/v% 
concentration (Gel-3) as the maximum non-toxic con-
centrations, and used them as the first concentrations for 
the 1:2 dilution series in subsequent experiments.
Direct qPCR measurement of the inhibition of HSV‑2 
replication by antiviral compounds
We applied our recently developed direct qPCR method 
[13] to assess the impact of vaginal gels on HSV-2 repli-
cation. We infected HeLa cells with HSV-2 in the pres-
ence of serial dilutions of the vaginal gels, starting with 
the maximum non-toxic concentrations (Fig.  1). Based 
on their impact on HSV-2 replication, the four tested gels 
could be divided into two groups. Gel-1 and Gel-2 were 
not able to inhibit HSV-2 replication even at the highest 
applied concentration, while Gel-3 and Gel-4 strongly 
inhibited HSV-2 replication at the maximum applied 
concentrations. In the case of Gel-3, the HSV-2 replica-
tion inhibition was 98.2%, and for Gel-4 the replication 
inhibition was 98.1%. Further dilutions of all the four gels 
behaved similarly: reduced to a lesser amount or slightly 
increased the replication of HSV-2. To evaluate whether 
the antiviral activity of Gel-3 and Gel-4 could be detected 
against different viral loads, we performed experiments 
with MOIs ranging from 0.4 to 6.4 (Fig.  2a). Similar to 
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the previous experiments, Gel-3 and Gel-4 had a ~ 99% 
inhibitory effect in the 0.4–6.4 MOI range. In correlation 
with their significant antiviral activity, Gel-3 and Gel-4 
also prevented the cytopathic effect of HSV-2 at MOI 6.4 
and MOI 1.6 (Fig. 2b).
The impact of vaginal gels on surface tension
To assess the potential detergent activity of the vaginal 
gels, we measured their surface tension decreasing effect. 
The measured surface tension values of the vaginal gel 
dilutions were plotted against the logarithm of the total 
concentration at 25 ± 0.02 °C (Fig. 3a, inset) and the dif-
ference between surface tensions measured the mini-
mum and maximum gel concentrations were calculated. 
Gel-3 and Gel-4 had the highest surface tension decreas-
ing effect with 18  mN/m and 33  mN/m respectively, 
while Gel-1 and Gel-2 only minimally decreased the 
surface tension (5.9  mN/m and 0.8  mN/m respectively) 
(Fig. 3a). The surface tension decreasing effects strongly 
correlated with the HSV-2 replication inhibitory activity 
 (R2 0.88) (Fig. 3b).
Discussion
We tested four commercially available vaginal gels 
to assess their HSV-2 replication modulating activity 
in vitro. Our data showed that the tested gels either had 
an approximately neutral effect (Gel-1, Gel-2) or strong 
inhibitory effect (Gel-3, Gel-4) at the highest tested 
concentration (10–20  w/v%). Since for Gel-3 and Gel-
4, the tested 10–20 w/v% concentrations mean in effect 
Fig. 1 Assessment of the impact of vaginal gels on HSV-2 replication. 
HeLa cells were infected with HSV-2 preincubated (1 h, 37 ℃) 
with 20–2.5 w/v% concentrations of Gel-1, Gel-2, Gel-4 gels and 
10–1.25 w/v% concentrations of Gel-3. At 24 h post infection, the 
cells were lysed and the HSV-2 DNA concentration was measured 
by direct qPCR. Statistical comparison of HSV-2 replication (Ct values 
of treated samples vs untreated controls (n = 3)) was performed by 
Student’s t-test. *P < 0.05, **P < 0.01
Fig. 2 Evaluation of the impact of Gel-3 and Gel-4 on HSV-2 replication and the inhibition of the HSV-2 induced cytopathic effect. a HeLa cells were 
infected with HSV-2 (MOI 6.4–0.4) preincubated (1 h, 37 ℃) with 10 w/v% and 20 w/v% concentrations of Gel-3 and Gel-4, respectively. At 24 h post 
infection, the cells were lysed and the HSV-2 DNA concentration was measured by direct qPCR (n = 3). b HeLa cells were infected with untreated 
and Gel-3 and Gel-4 treated HSV-2 (MOI 6.4 and MOI 1.6), as described before. HSV-2 cytopathic effect was compared to the untreated HeLa cells by 
light microscopy 24 h post infection
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a five-tenfold dilution, and considering that the volume 
of vaginal fluid and sperm lies in the 1–3 mL range [17, 
18], one may expect that in  vivo these gels can achieve 
10–20  w/v% or higher concentrations and have sig-
nificant antiviral activity. As during the symptomatic 
infection the sexual activity is likely abandoned, HSV-2 
transmission via shedding during the asymptomatic peri-
ods and in the very early phase of symptomatic infections 
is probably more frequent. Daily testing of HSV-2 sero-
positive individuals revealed that asymptomatic HSV-2 
shedding occurred in 2–3.8% of the days [19, 20], indi-
cating that asymptomatic HSV-2 shedding is a relatively 
frequent event. Schiffer et  al. showed that for 14,685 
swab samples, 18% were HSV-2 positive (> 150 DNA cop-
ies/ml), and close to 90% of the samples contained more 
than  104 DNA copies/mL [21]. Since the median HSV-2 
load was  104.8 DNA copies/mL [21] and the threshold of 
HSV-2 transmission was calculated previously as > 104 
infectious unit (IFU) [22], even a low level HSV-2 load 
decrease could be significant in preventing the transmis-
sion. Gel-3 and Gel-4 were able to cause ~ 2 logs decrease 
in HSV-2 IFU and were effective at least at 6.4 MOIs 
(~ 400,000 IFUs), therefore these gels might lower the 
risk of transmission, despite the fact that they were not 
designed for prevention. Altogether, these results high-
light the importance of evaluation of commercially avail-
able vaginal gels/lubricants for their possible anti-HSV-2 
activity before investigating their role in the prevention 
of HSV-2 transmission [23].
As the commercially available gels generally contain 
several ingredients in unknown concentrations, the 
exact sources of the cumulative inhibitory activity are 
not known. As an example, a potentially antimicrobial 
unique component of Gel-4 gel was the “citrus aroma”. 
It was described previously, that citrusinine-I, an alka-
loid isolated from the citrus plant Rutaceae displayed 
antiviral activity against HSV-1 and HSV-2 [24]. Among 
the physicochemical attributes of the vaginal gels, one is 
their hydrophilic, hydrophobic or amphipathic nature. 
Amphipathic gel components can behave as surfactants, 
providing a detergent-like activity for the gels. HSV-2 is 
an enveloped virus, hence the detergent activity could 
destabilize the viral membrane and decrease viral infec-
tivity [25]. We measured the surface tension decreasing 
activity of the gels which correlates with their detergent-
like activity. Gel-3 and Gel-4 showed a marked detergent-
like activity, while Gel-1 and Gel-2 had negligible effect. 
Our results also showed that detergent-like activity and 
the in  vitro antiviral activity of the gels were strongly 
correlated, a finding that may be used in future gel 
developments.
Limitations
A limitation of our study, that we did not investigate the 
in vivo antiviral effects of the gels. Previous data show 
that in vivo a marked detergent-like activity may actu-
ally increase HSV-2 susceptibility. In a mouse model 
of HSV-2 infection, all the five intravaginally applied 
detergent containing gels increased HSV-2 susceptibil-
ity [26]. This effect was likely due to the in vivo deter-
gent cytotoxicity, which led to injury and shedding of 
the epithelial cells from the upper layers of the mucosa. 
It is possible that there is an optimal detergent con-
centration where the viral membrane is destabilized, 
Fig. 3 Association between the surface tension decreasing effects and the antiviral effects of the vaginal gels. a Surface tension decreasing activity 
of the tested gels. Surface tension decrease was calculated by subtraction of surface tension in the minimum gel concentration and surface tension 
in the maximum gel concentration. Insert shows surface tension decrease by Gel-4 as a function of  log10 gel concentration. b Correlation between 
the surface tension decreasing activity and the average HSV-2 replication measured at the maximum gel concentration. Pearson correlation 
coefficient is also shown
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but the epithelial layer of the cervix remains intact. 
Regarding the selective toxicity, two of the four tested 
gels showed significant anti-HSV-2 activity but had no 
impact on the viability of the host cells in the 1:5 and 
1:10 dilutions (20 w/v% and 10 w/v%). However there is 
room for further development, e.g. Gel-3 showed anti-
HSV-2 activity only in its first non-toxic concentration.
In conclusion, our experiments revealed that there 
are substantial differences among commercially avail-
able vaginal gels regarding their anti-HSV-2 activity. 
From the tested four gels we found two with a signifi-
cant antiviral activity, suggesting that these gels might 
be able to decrease the frequency of HSV-2 transmis-
sion. Further experiments are needed to evaluate their 
overall effect on HSV-2 infectivity in vivo.
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Additional file 1: Figure S1. MTT cell viability assay of HeLa cells 
incubated with the vaginal gels. Viability of the gel-treated cells were 
compared to the untreated controls. Data are mean ± SD (n = 3). Statisti-
cal comparisons of cell viabilities (treated vs. untreated control) were 
performed by Student’s t-test. *: P < 0.05.
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